First international workshop of the ATM and cancer risk group (4-5 December 2019)

F Lesueur; DF Easton; AL Renault; SV Tavtigian; JL Bernstein; Z Kote-Jarai; RA Eeles; D Plaseska-Karanfia; L Feliubadaló; A Moles-Fernández; M Santamariña-Pena; AT Sánchez; A López-Novo; LM Porras; A Blanco; G Capellá; M de la Hoya; IJ Molina; A Osorio; M Pineda; D Rueda; X de la Cruz; O Diez; C Ruiz-Ponte; S Gutiérrez-Enríquez; A Vega; C Lázaro; B Arun; N Herold; B Versmold; RK Schmutzler; T Nguyen-Dumont; MC Southey; L Dorling; AM Dunning; P Ghiorzo; BS Dalmasso; E Cavaciuti; D Le Gal; NJ Roberts; M Dominguez-Valentin; M Rookus; AMR Taylor; AM Goldstein; DE Goldgar; F Couch; P Kraft; J Weitzel; K Nathanson; S Domchek; H LaDuca; D Stoppa-Lyonnet; N Andrieu

Journal article

First international workshop of the ATM and cancer risk group (4-5 December 2019)

F Lesueur, DF Easton, AL Renault, SV Tavtigian, JL Bernstein, Z Kote-Jarai, RA Eeles, D Plaseska-Karanfia, L Feliubadaló, A Moles-Fernández, M Santamariña-Pena, AT Sánchez, A López-Novo, LM Porras, A Blanco, G Capellá, M de la Hoya, IJ Molina, A Osorio, M Pineda Show all

Familial Cancer | Published : 2022

DOI: 10.1007/s10689-021-00248-y

Abstract

The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated by the fact that germline ATM pathogenic variants have been found to be associated with different cancer types. However, due to the lack of precise age-, sex-, and site-specific risk estimates, no consensus on management guidelines for variant carriers exists, and the clinical utility of ATM variant testing is uncertain. The meeting brought together epidemiologists, geneticists, biologists and clinicians to review current knowledge and on-going challenges related to ..

View full abstract